news > tag > radiopharmaceuticals

United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting

Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar

isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)

Tags:

First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera

Kevin Yang ⎜Mar 20, 2018 ⎜ Industry

99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.

The WATERDAY study: Denis Agostini & Vincent (more…)

Tags:

99mTc-maraciclatide SPECT for prostate cancer bone metastases

Kevin Yang ⎜Mar 12, 2018 ⎜ Industry

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)

Tags:

isoSolutions Customer Wins Distinguished Scientist Award

David T. Drummond ⎜Oct 24, 2017 ⎜ Company

“Vancouver, BC – The Western Region Society of Nuclear Medicine (WRSNM) will honor Dr. François Bénard from the BC Cancer Agency with the presentation of their Distinguished Scientist Award. … Dr. Bénard is the Vice President, Research at the BC Cancer Agency, a Distinguished Scientist at the BC Cancer Agency Research Centre and Professor in the Department of Radiology at the University of British Columbia. He is also Associate Dean, Research at the University of British Columbia. In addition he holds the BC Leadership Chair in Functional Cancer Imaging. As a clinician scientist, his research interests are in positron emission tomography (PET), nuclear medicine, cancer imaging and targeted radionuclide therapy. (more…)

Tags:

Automation of the Radiosynthesis of Six Different 18 F-labeled radiotracers on the AllinOne

David T. Drummond ⎜Nov 15, 2016 ⎜ Products

Background
Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible manner. The aim of this study was to develop automated synthesis methods for these six 18F-labeled radiopharmaceuticals produced on a routine basis at the University of Pennsylvania using (more…)

Tags:

UPENN 2016 Automation of the Radiosynthesis of Six radiotracers

David T. Drummond ⎜Sep 24, 2016 ⎜ Products

[18F]ISO-1,
[18F]FTT,
[18F]FTP,
[18F]Fallypride,
[18F]Flubatine and
[18F]F-G
ln produced on a routine basis at UPENN with the Trasis AllinOne synthesizer.

By Ramona Delcea, Trasis Download pdf

Tags: